Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Vuk Bortnik"'
Autor:
Vuk Bortnik, Michelle Wu, Bryan Julcher, Ana Salinas, Iva Nikolic, Kaylene J. Simpson, Nigel AJ. McMillan, Adi Idris
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 54, Iss 4, Pp 733-739 (2021)
Human papilloma viruses (HPV) are the main culprit in cervical and oropharyngeal cancers. HPV positive (+) cancers are regarded as ‘oncogene addicted’, displaying an absolute requirement for the continued expression of the oncogenes for their via
Externí odkaz:
https://doaj.org/article/c2b05c7d18f74307a50fa465acbbec9b
Autor:
Silvia Cecilia Pacheco-Velázquez, Rafael Moreno-Sánchez, Vuk Bortnik, Stephen John Ralph, Rhys Pritchard, Sara Rodríguez-Enríquez
Publikováno v:
Biochemical Pharmacology. 154:318-334
Capecitabine induced toxicities such as hand-foot syndrome (HFS) and progression of metastatic cancer are both treatable with concurrent celecoxib as shown in the ADAPT (Activating Cancer Stem Cells from Dormancy And Potentiate for Targeting) trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e28831e2b7fb384045546ae5f2d054e
https://doi.org/10.1016/j.bcp.2018.05.013
https://doi.org/10.1016/j.bcp.2018.05.013
Publikováno v:
Microbial pathogenesis. 132
Head and neck cancers (HNCs) are a major health problem and a leading cause of morbidity and mortality worldwide. More than 90% of these tumours are head and neck squamous cell carcinomas (HNSCCs). Amongst the common risk factors for HNCs (tobacco an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::858cad0945ec8c0cd6d4794084269f94
https://pubmed.ncbi.nlm.nih.gov/31054871
https://pubmed.ncbi.nlm.nih.gov/31054871
Autor:
Rhys, Pritchard, Sara, Rodríguez-Enríquez, Silvia Cecilia, Pacheco-Velázquez, Vuk, Bortnik, Rafael, Moreno-Sánchez, Stephen, Ralph
Publikováno v:
Biochemical pharmacology. 154
Capecitabine induced toxicities such as hand-foot syndrome (HFS) and progression of metastatic cancer are both treatable with concurrent celecoxib as shown in the ADAPT (Activating Cancer Stem Cells from Dormancy And Potentiate for Targeting) trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2ed55d97dd62ab5555e790b5fe246795
https://pubmed.ncbi.nlm.nih.gov/29800556
https://pubmed.ncbi.nlm.nih.gov/29800556